Suven Neurosciences

Suven Neurosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. As a subsidiary of Suven Life Sciences, the company primarily manages the clinical development of its lead assets in the United States and Europe. Its pipeline features several small molecule candidates targeting various neurotransmitter receptors to treat conditions such as Alzheimer's disease, narcolepsy, and major depressive disorder. The lead program, Masupirdine (SUVN-502), is currently undergoing Phase 3 clinical trials for the treatment of agitation associated with Alzheimer's-type dementia. The company leverages the extensive discovery research capabilities of its parent organization to advance its portfolio through global regulatory pathways.